HMN-214 is primarily used in research settings as a potent and selective inhibitor of the NAMPT enzyme (nicotinamide phosphoribosyltransferase), which plays a key role in the biosynthesis of NAD+, a critical coenzyme involved in cellular metabolism and energy production. By targeting NAMPT, HMN-214 disrupts NAD+ synthesis in cancer cells, leading to energy depletion and cell death, making it a compound of interest in oncology research, particularly for hematological malignancies and solid tumors. Its application extends to studies exploring metabolic dependencies in tumor cells and the role of NAD+ in DNA repair mechanisms, especially when combined with other anticancer agents like PARP inhibitors or chemotherapeutics. Due to its ability to cross the blood-brain barrier, HMN-214 is also investigated for potential activity against central nervous system tumors or metastases. Currently, HMN-214 remains a preclinical research tool and is not approved for therapeutic use, but it serves as a valuable molecule for validating NAMPT as a drug target and for developing novel cancer treatment strategies.